enolase-phosphatase 1Genealiases: E1 · MASA · MST145 · mtnC
Q-omics provides the consensus-scored ENOPH1 profile across patient tissues and cancer cell-line models. ENOPH1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, ENOPH1 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, ENOPH1 protein abundance shows 25,252 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight LIHC, COAD, and PDAC as cancer lineages where ENOPH1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ENOPH1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ENOPH1 survival associations across molecular data types. ENOPH1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ENOPH1 RNA expression–survival associations across cancer types. High ENOPH1 expression shows unfavorable associations in LIHC, KICH and UVM, but favorable associations in UCEC, KIRC and READ. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for ENOPH1 RNA expression.
This table summarizes ENOPH1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ENOPH1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ENOPH1 shows higher tumor expression in COAD, HNSC, BLCA, STAD, LUAD and LIHC. The COAD box plot shows higher ENOPH1 RNA expression in tumor versus normal tissue (log2 FC = +1.448, t-test p < 0.001).
This table shows molecular features associated with ENOPH1 in patient tissues and cancer cell lines. In patient samples, ENOPH1 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, ENOPH1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SKIN.
